February 6, 2023

Valley Post

Read Latest News on Sports, Business, Entertainment, Blogs and Opinions from leading columnists.

Moderna: Vaccine cost is in the works

the accident You will price the vaccine against coronavirus next time. The price listed in the schedule ranges from $110 to $130 a dose in the United States, and is set to take effect when it moves from government contracting to commercial distribution of vaccines.

According to a Wall Street Journal report, the price range under consideration is similar to that of Pfizer Inc. It said in October that it was studying the vaccine it developed with BioNTech SE.

What the CEO of Moderna said

“I think that kind of pricing is consistent with the value” offered by the vaccine, Moderna CEO Stéphane Bancel said in an interview Monday on the sidelines of a JP Morgan healthcare conference in San Francisco.

It also said the expected price for commercial insurers would be much higher than the cost of a dose in supply contracts with the federal government.

How much do booster shots cost?

Moderna’s upgraded booster vaccines cost about $26 per dose under a federal supply contract signed in July 2022. The original vaccine cost about $15 to $16 a dose under previous supply contracts.

So far, the federal government has purchased all doses of Covid-19 vaccines and made them freely available to consumers. After supplies guaranteed under federal contracts run out, US officials said, companies will have to turn to standard commercial distribution.

In discussions with hospitals and pharmacies

Mr. Bancel said Moderna is in talks with hospital and pharmacy systems and pharmacy benefit managers to align distribution of its vaccine ahead of a potential campaign to suggest people get the booster drug in the fall.

See also  Google's new big investment in cloud infrastructure in Greece

Mr Bancel said the booster doses distributed in the fall may be updated to match circulating variants of the coronavirus. Even as prices per dose rise, sales of Moderna’s Covid-19 vaccine are expected to decline.

Vaccine sales are expected to be low

The Cambridge, Massachusetts-based company said Monday that it expects sales of Covid-19 vaccines to reach a bottom line of about $5 billion by 2023, with an option to buy more doses. For the whole of 2022, sales of Covid-19 vaccines were recorded at about $18.4 billion.

The company is increasing its focus on potential new products beyond a Covid-19 vaccine, such as a respiratory virus vaccine, or RSV. Moderna expects to report results soon from a large study of its RSV vaccine, Bancel said.